Teva launches migraine treatment patch in US


ZECUITY is a disposable patch system, worn for four-hours on the upper arm or thigh, that delivers sumatriptan through the skin.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced that ZECUITY, a patch system designed to provide relief from migraine, is now available by prescription in the US. ZECUITY is a single-use, disposable patch system that delivers sumatriptan through the skin. The device is designed to be worn for a four-hour period either on the upper arm or thigh.

An estimated 36 million people in the US suffer from migraine.

“Migraine sufferers experiencing nausea as part of their migraine may delay or avoid treatment and may seek non-oral treatment options,” said Teva president, global R&D and Chief Scientific Officer Dr. Michael Hayden, “At Teva, we are committed to delivering innovative treatments that improve patient care and are proud to offer ZECUITY to people looking for a different route to migraine relief.”

In a clinical study, at two hours following application, significantly more patients using ZECUITY versus a non-medicated patch system reported, as the study’s primary endpoint, no headache pain (18% versus 9%). The secondary endpoints of the study showed that, at two hours following application, significantly more patients reported no nausea (84% versus 63%), no sensitivity to sound (55% versus 39%), no sensitivity to light (51% versus 36%), or headache pain relief (53% versus 29%). The most common side effects reported for ZECUITY included pain, tingling, itching, warmth, discomfort or a change in the skin color at the application site of ZECUITY.

Published by Globes [online], Israel business news - - on September 1, 2015

© Copyright of Globes Publisher Itonut (1983) Ltd. 2015

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017